

# Active substances set

**Search phrase:** asciminib

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

## Chronic myeloid leukemia

| | | |
|---|---|---|
| **Asciminib** | Asciminib is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors. | REIMBURSEMENT WITH RESTRICTIONS<br>ESMO |